Edwards Lifesciences (EW) reported $6.1B in revenue for fiscal 2025, +11.5% year on year. That ranks #713 by revenue among 2853 SEC filers and #62 in Healthcare. Net income was $1.1B, a net margin of 17.7%. Revenue has grown 8.3% a year on average since 2016 ($3.0B then). The fiscal 2025 balance sheet shows $13.7B in total assets, $2.9B in cash and $598M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $6.1B | +11.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $4.7B | +9.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $1.3B | −8.3% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.1B | −74.3% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.6B | +194.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $260M | +3.1% | FY20252025-12-31 |
| Total assetsAssets | $13.7B | +4.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $10.3B | +3.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $2.9B | −3.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $598M | +0.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $1.6B | $381M | Open → |
| Q2 20262026-06-30 | $1.7B | $242M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 29 of 161 companies compared | 17.7% | |
| Operating marginRank 33 of 160 companies compared | 20.8% | |
| R&D as share of revenueRank 31 of 102 companies compared | 17.8% | |
| Cash as share of revenueRank 8 of 160 companies compared | 48.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Edwards Lifesciences Corp
- Ticker
- EW
- Exchange
- NYSE
- SIC classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- Fiscal year end
- 12-31
- CIK
- 0001099800
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ardent HealthARDT | $6.3B | $136M |
| OrganonOGN | $6.2B | $187M |
| Smith & NephewSNN | $6.2B | $625M |
| Edwards LifesciencesEW | $6.1B | $1.1B |
| SterisSTE | $5.9B | $782M |
| Encompass HealthEHC | $5.9B | $566M |
| Agilon HealthAGL | $5.9B | −$391M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Edwards Lifesciences — Key figures |url=https://companiesranked.com/en/company/edwards-lifesciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Edwards Lifesciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/edwards-lifesciencesBibTeX
@misc{companiesranked-en-company-edwards-lifesciences-2026,
author = {{CompaniesRanked}},
title = {{Edwards Lifesciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/edwards-lifesciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001099800-26-000009 · February 25, 2026
{{cite web |title=Edwards Lifesciences — Key figures — 10-K (0001099800-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.